For Q1 FY2026 (ended March 31, 2026), Biogen reported revenue of $2.48 billion, up 1.9% year-over-year. Net income was $319.5 million, a 32.8% increase, while diluted EPS rose 31.1% to $2.15. Operating income was $610.7 million, down 37.3% from the prior year. Long-term debt stood at $6.29 billion.
•Revenue increased 1.9% YoY to $2.48 billion.
•Net income rose 32.8% to $319.5 million; diluted EPS up 31.1% to $2.15.
•Operating income declined 37.3% to $610.7 million.
•Long-term debt was $6.29 billion as of March 31, 2026.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Biogen Inc. discovers develops, manufactures, and delivers therapies globally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS).
Its portfolio also includes SPINRAZA for spinal muscular atrophy, SKYCLARYS to treat Friedreich's Ataxia, QALSODY for treating amyotrophic lateral sclerosis, FUMADERM to treat plaque psoriasis, BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease.
Its portfolio also includes ZURZUVAE for the treatment of postpartum depression, RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris, RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL, GAZYVA to treat CLL and follicular lymphoma, OCREVUS for relapsing MS and primary progressive MS, LUNSUMIO to treat relapsed or refractory follicular lymphoma, glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma, and anti-CD20 therapies.
Biogen Inc. has collaboration and license agreements with Merz Therapeutics. Its portfolio also includes Alkermes Pharma Ireland Limited, Denali Therapeutics Inc., UCB, Eisai Co., Ltd., Genentech, Inc., Neurimmune SubOne AG, Ionis Pharmaceuticals, Inc., Samsung Bioepis, Sage Therapeutics, Inc.
Collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome, Dayra Therapeutics, Inc. to develop oral macrocyclic peptides, Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound, City Therapeutics, Inc. to develop select novel RNAi therapies, and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. Founded in 1978, the company is headquartered in Cambridge, Massachusetts.
What does Biogen Inc. do and what are its main products?
Biogen Inc. discovers, develops, manufactures, and delivers therapies globally. Its portfolio includes treatments for multiple sclerosis such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI. For spinal muscular atrophy, it offers SPINRAZA. SKYCLARYS treats Friedreich's Ataxia, QALSODY treats amyotrophic lateral sclerosis, and FUMADERM treats plaque psoriasis. Biogen also markets biosimilars like BENEPALI (etanercept), IMRALDI (adalimumab), and FLIXABI (infliximab). For Alzheimer's disease, it offers LEQEMBI, and for postpartum depression, ZURZUVAE. Additionally, it provides anti-CD20 therapies such as RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS, LUNSUMIO, and glofitamab for various cancers and autoimmune conditions.
Where is Biogen listed and what currency does it trade in?
Biogen Inc. is listed on the NasdaqGS exchange under the ticker symbol BIIB. Its shares are traded in US dollars (USD). The company is headquartered in the United States and operates primarily in the US market, though its therapies are delivered globally.
What sector and industry does Biogen belong to?
Biogen Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - General industry. This means Biogen is a pharmaceutical company that develops, manufactures, and markets a wide range of drugs, including treatments for neurological disorders, autoimmune diseases, and cancers. The 'General' classification indicates it produces various types of medications rather than specializing in a single therapeutic area.
What are some notable collaborations and partnerships of Biogen?
Biogen has several collaboration and license agreements. It partners with Merz Therapeutics, Alkermes Pharma Ireland Limited, Denali Therapeutics Inc., UCB, Eisai Co., Ltd., Genentech, Inc., Neurimmune SubOne AG, Ionis Pharmaceuticals, Inc., Samsung Bioepis, and Sage Therapeutics, Inc. Additionally, Biogen collaborates with Stoke Therapeutics, Inc. to develop and commercialize zorevunersen, a disease-modifying medicine for certain conditions. These partnerships help Biogen expand its pipeline and bring innovative therapies to market.
What is Biogen's geographic focus and headquarters location?
Biogen Inc. is headquartered in the United States and its primary region of operation is the US market, as indicated by its region code 'us'. The company delivers therapies globally, meaning its products are available in many countries worldwide. While the specific headquarters city is not provided in the data, Biogen is a US-based multinational biopharmaceutical company with a significant international presence.